By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

Investing.com - UBS has reiterated its Buy rating on ResMed (NYSE:RMD) with a price target of $345.00, according to a recent analyst note. The stock currently trades at $261.13, representing a ...

Sleep has become a battleground for technology firms, insurers and health providers, with significant money riding on what happens overnight. Once treated as a personal habit, sleep now features in ...

A sleep apnea implant sends a signal to move the tongue and keep the airway open while you sleep. To qualify for the implant, you must have a BMI of less than 35 and cannot tolerate a CPAP device. The ...

The FDA announced it planned to restrict use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, including those from Hims & Hers and other compounding pharmacies.